메뉴 건너뛰기




Volumn 37, Issue 4, 2017, Pages 500-502

Finding the cure for primary biliary cholangitis – Still waiting

Author keywords

biological therapy; primary biliary cholangitis; tolerance

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; CYTOKINE; OBETICHOLIC ACID; URSODEOXYCHOLIC ACID; BIOLOGICAL MARKER; CHENODEOXYCHOLIC ACID; CHOLAGOGUE;

EID: 85016485058     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13344     Document Type: Article
Times cited : (22)

References (17)
  • 1
    • 84988421413 scopus 로고    scopus 로고
    • Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance
    • Bae HR, Leung PS, Tsuneyama K, et al. Chronic expression of interferon-gamma leads to murine autoimmune cholangitis with a female predominance. Hepatology. 2016;64:1189–1201.
    • (2016) Hepatology , vol.64 , pp. 1189-1201
    • Bae, H.R.1    Leung, P.S.2    Tsuneyama, K.3
  • 2
    • 84959064216 scopus 로고    scopus 로고
    • Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis
    • Choi J, Selmi C, Leung PS, et al. Chemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis. Expert Rev Clin Immunol. 2016;12:661–672.
    • (2016) Expert Rev Clin Immunol , vol.12 , pp. 661-672
    • Choi, J.1    Selmi, C.2    Leung, P.S.3
  • 3
    • 84976519930 scopus 로고    scopus 로고
    • Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study
    • Hirschfield GM, Gershwin ME, Strauss R, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study. Hepatology. 2016;64:189–199.
    • (2016) Hepatology , vol.64 , pp. 189-199
    • Hirschfield, G.M.1    Gershwin, M.E.2    Strauss, R.3
  • 4
    • 84953306524 scopus 로고    scopus 로고
    • AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis
    • Hsueh YH, Chang YN, Loh CE, Gershwin ME, Chuang YH. AAV-IL-22 modifies liver chemokine activity and ameliorates portal inflammation in murine autoimmune cholangitis. J Autoimmun. 2016;66:89–97.
    • (2016) J Autoimmun , vol.66 , pp. 89-97
    • Hsueh, Y.H.1    Chang, Y.N.2    Loh, C.E.3    Gershwin, M.E.4    Chuang, Y.H.5
  • 5
    • 84953345460 scopus 로고    scopus 로고
    • Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways
    • Hudspeth K, Donadon M, Cimino M, et al. Human liver-resident CD56(bright)/CD16(neg) NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun. 2016;66:40–50.
    • (2016) J Autoimmun , vol.66 , pp. 40-50
    • Hudspeth, K.1    Donadon, M.2    Cimino, M.3
  • 6
    • 84962106535 scopus 로고    scopus 로고
    • A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis
    • Leung PS, Choi J, Yang G, et al. A contemporary perspective on the molecular characteristics of mitochondrial autoantigens and diagnosis in primary biliary cholangitis. Expert Rev Mol Diagn. 2016;16:697–705.
    • (2016) Expert Rev Mol Diagn , vol.16 , pp. 697-705
    • Leung, P.S.1    Choi, J.2    Yang, G.3
  • 7
    • 84957434981 scopus 로고    scopus 로고
    • Differential phenotypic and functional properties of liver-resident NK cells and mucosal ILC1s
    • Tang L, Peng H, Zhou J, et al. Differential phenotypic and functional properties of liver-resident NK cells and mucosal ILC1s. J Autoimmun. 2016;67:29–35.
    • (2016) J Autoimmun , vol.67 , pp. 29-35
    • Tang, L.1    Peng, H.2    Zhou, J.3
  • 8
    • 84928587439 scopus 로고    scopus 로고
    • Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis
    • Wang YH, Yang W, Yang JB, et al. Systems biologic analysis of T regulatory cells genetic pathways in murine primary biliary cirrhosis. J Autoimmun. 2015;59:26–37.
    • (2015) J Autoimmun , vol.59 , pp. 26-37
    • Wang, Y.H.1    Yang, W.2    Yang, J.B.3
  • 9
    • 84946472960 scopus 로고    scopus 로고
    • The immunogenetics of primary biliary cirrhosis: a comprehensive review
    • Webb GJ, Siminovitch KA, Hirschfield GM. The immunogenetics of primary biliary cirrhosis: a comprehensive review. J Autoimmun. 2015;64:42–52.
    • (2015) J Autoimmun , vol.64 , pp. 42-52
    • Webb, G.J.1    Siminovitch, K.A.2    Hirschfield, G.M.3
  • 10
    • 85016475353 scopus 로고    scopus 로고
    • Old and new treatments for primary biliary cholangitis
    • Chascsa D, Carey E, Lindor K. Old and new treatments for primary biliary cholangitis. Liver Int 2017;37:490–499.
    • (2017) Liver Int , vol.37 , pp. 490-499
    • Chascsa, D.1    Carey, E.2    Lindor, K.3
  • 11
    • 84982102773 scopus 로고    scopus 로고
    • A placebo-controlled trial of obeticholic acid in primary biliary cholangitis
    • Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–643.
    • (2016) N Engl J Med , vol.375 , pp. 631-643
    • Nevens, F.1    Andreone, P.2    Mazzella, G.3
  • 12
    • 84949105616 scopus 로고    scopus 로고
    • The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis
    • Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63:930–950.
    • (2016) Hepatology , vol.63 , pp. 930-950
    • Carbone, M.1    Sharp, S.J.2    Flack, S.3
  • 13
    • 84952986849 scopus 로고    scopus 로고
    • Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy
    • e4
    • Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;149:1804–1812. e4.
    • (2015) Gastroenterology , vol.149 , pp. 1804-1812
    • Lammers, W.J.1    Hirschfield, G.M.2    Corpechot, C.3
  • 15
    • 84891921511 scopus 로고    scopus 로고
    • Guidelines for the management of primary biliary cirrhosis: the Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan
    • Working Subgroup for Clinical Practice Guidelines for Primary Biliary C. Guidelines for the management of primary biliary cirrhosis: the Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res 2014;44(Suppl S1):71–90.
    • (2014) Hepatol Res , vol.44 , pp. 71-90
  • 16
    • 84982170263 scopus 로고    scopus 로고
    • Primary biliary cholangitis–A new name and a new treatment
    • Pratt DS. Primary biliary cholangitis–A new name and a new treatment. N Engl J Med. 2016;375:685–687.
    • (2016) N Engl J Med , vol.375 , pp. 685-687
    • Pratt, D.S.1
  • 17
    • 84992602694 scopus 로고    scopus 로고
    • From old concerns to new advances and personalized medicine in lupus: the end of the tunnel is approaching
    • Doria A, Gershwin ME, Selmi C. From old concerns to new advances and personalized medicine in lupus: the end of the tunnel is approaching. J Autoimmun. 2016;74:1–5.
    • (2016) J Autoimmun , vol.74 , pp. 1-5
    • Doria, A.1    Gershwin, M.E.2    Selmi, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.